For decades, India has earned global recognition as the “pharmacy of the world.” The country supplies nearly 20% of the world’s generic medicines by volume, operates one of the largest pharmaceutical manufacturing ecosystems, and has built formidable capabilities in affordability, scale, and access. Yet, one critical therapeutic segment remains largely untapped by Indian innovation: Women’s health.

Despite serving over half of the global population, women’s health continues to be one of the most under-invested areas in healthcare innovation. Today, the global women’s health market is valued at more than US$53 billion and is projected to exceed US$75 billion by 2033, driven by increasing awareness, rising incidence of chronic conditions, expanding access to reproductive healthcare, and growing demand for personalized therapies. The most striking reality, however, is that only a handful of multinational pharmaceutical companies dominate the market.

Women’s Health- A Market Controlled by Global Innovators

Companies such as Pfizer, Bayer, AbbVie, Amgen, and Merck Group collectively command a significant share of the global women’s health landscape through proprietary therapies, contraceptive technologies, fertility solutions and treatments for conditions such as endometriosis, menopause, uterine fibroids, and osteoporosis. Their competitive advantage is not manufacturing scale, it is intellectual property.

From Bayer’s leadership in intrauterine devices through Mirena to Pfizer’s expanding women’s health portfolio, global players have invested billions of dollars in discovery research, clinical trials, regulatory approvals, and commercialization. Innovation, rather than volume, drives value creation.

India’s Strength: Scale, Affordability and Distribution

India’s pharmaceutical ecosystem tells a different story. Leading companies have built strong women’s health portfolios focused on accessibility and affordability:

• Lupin has established a dedicated presence in gynaecology and contraceptive care.
• Zydus has expanded its offerings in pregnancy and antenatal health.
• Torrent Pharma strengthened its women’s health portfolio through strategic acquisitions.
• Mankind Pharma has built highly recognizable consumer brands across pregnancy detection, fertility, and emergency contraception.

These companies have succeeded by addressing large domestic needs through efficient manufacturing, extensive physician engagement, and robust distribution networks. However, most products remain formulation-led or generic offerings rather than globally patented innovations. As a result, Indian companies participate primarily in established markets instead of creating entirely new therapeutic categories.

Why Has India Lagged in Women’s Health Innovation?

The reasons are structural rather than strategic.

1. A Legacy Focus on Access and Affordability

India’s patent ecosystem has historically prioritized access to essential medicines, enabling affordable healthcare at scale and fostering a thriving generics industry. While this model transformed global access to medicines, it created fewer incentives for high-risk, long-horizon pharmaceutical innovation.

2. Price Controls Limit Premiumization

Government mechanisms designed to keep essential medicines affordable have constrained pricing flexibility in several therapeutic areas. This environment naturally favors high-volume business models over breakthrough innovation.

3. Scale Has Outperformed R&D

For many Indian pharmaceutical companies, operational excellence, manufacturing efficiency, and market reach have generated stronger returns than investing in discovery research. Developing a novel therapy can require over a decade of research and billions of dollars in investment – with no guarantee of success.

4. Limited Investment in Global Clinical Development

Indian pharmaceutical companies have traditionally allocated lower budgets toward large-scale international clinical trials, regulatory filings, and intellectual property creation compared to global innovators. Building globally competitive women’s health brands requires deep expertise across translational research, clinical science, regulatory affairs, and lifecycle management.

The Opportunity Is Larger Than Ever

The innovation gap in women’s health is also its biggest opportunity. Conditions such as endometriosis, polycystic ovary syndrome (PCOS), infertility, menopause-related disorders, pelvic health conditions, and maternal health remain underserved globally. 

According to multiple studies, women spend significantly more years in poor health compared to men due to conditions that are often underdiagnosed, undertreated, or overlooked by traditional healthcare systems. This unmet need creates a significant white space for pharmaceutical companies willing to invest in differentiated solutions. 

For India, the timing could not be better as we already possess key ingredients for success:

• World-class scientific talent
• Cost-efficient R&D capabilities
• A rapidly growing biotechnology ecosystem
• Increasing government support for innovation
• Strong manufacturing infrastructure
• Expanding digital health capabilities

The missing link is sustained investment in original research around women’s health.

A Defining Moment: Sun Pharma’s Organon Bet

The recent US$11.75 billion acquisition of Organon by Sun Pharma could mark a turning point for India’s pharmaceutical industry. The transaction instantly positions Sun Pharma among the leading global players in women’s health while providing access to established brands, a presence in more than 140 countries, and deep expertise across contraception, fertility, and biosimilars. 

More importantly, the acquisition signals a strategic shift. Indian pharmaceutical companies are no longer content with being manufacturing partners to the world. Increasingly, they are seeking ownership of intellectual property, premium brands, and global commercial platforms. This evolution from volume-led growth to innovation-led growth, could redefine India’s role in the global pharmaceutical value chain.

Also read: India’s ₹12 Lakh Crore Pharma Powerhouses: The Companies Defining Global Healthcare in 2026

The Road Ahead

Can India build a globally patented women’s health brand within the next decade? The answer is yes, but only if the industry embraces a new operating model. Success will require:

• Greater investment in discovery research and translational science
• Stronger collaborations between academia, startups, and industry
• Expanded participation in global clinical trials
• Increased focus on intellectual property creation
• Dedicated innovation funding for women’s health
• A long-term commitment to solving unmet clinical needs

India transformed the economics of access to medicines over the last three decades. The next chapter could be even more ambitious: transforming the economics of innovation. The country that became the world’s pharmacy now has an opportunity to become one of the world’s most influential creators of women’s healthcare solutions. The question is no longer whether India has the capability. The question is whether it has the conviction to invest for the long term.

As India charts its transition from a volume-driven pharmaceutical powerhouse to an innovation-led global healthcare leader, platforms that foster collaboration across the ecosystem will become increasingly critical. This is where India Pharma Expo 2027 assumes greater significance. Scheduled for 11–13 March 2027 at the HITEX Exhibition Centre, Hyderabad, the expo will bring together pharmaceutical companies, researchers, policymakers, investors, health-tech innovators, and global partners to shape the future of life sciences and healthcare innovation.

If India is to build globally patented women’s health brands over the next decade, it will require more than scientific capability, it will require stronger partnerships, increased investment in R&D, and a shared vision for innovation. India Pharma Expo 2027 aims to provide exactly that platform: a catalyst for the conversations, collaborations, and breakthroughs that could define the next chapter of India’s pharmaceutical journey. Join us at https://indiapharmaexpo.com/visitor.php

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

Disclaimer: The views and opinions expressed in this article are solely those of the author and do not necessarily reflect the official policy or views of any organisation. The content is intended for informational and educational purposes only and should not be construed as medical advice.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!